Edition:
United Kingdom

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

67.42EUR
15 Oct 2018
Change (% chg)

€1.14 (+1.72%)
Prev Close
€66.28
Open
€65.96
Day's High
€67.50
Day's Low
€65.88
Volume
1,145,801
Avg. Vol
1,303,512
52-wk High
€72.76
52-wk Low
€58.96

Latest Key Developments (Source: Significant Developments)

Fresenius Kabi Biosimilar Candidate Meets Primary Endpoints In Two Studies
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Fresenius SE & Co KGaA ::FRESENIUS KABI BIOSIMILAR CANDIDATE MEETS PRIMARY ENDPOINTS IN THE TWO PIVOTAL CLINICAL STUDIES.FRESENIUS KABI HAS REACHED A MILESTONE ON THE ROAD TO APPROVAL FOR ANOTHER BIOSIMILAR.MSB11455, A BIOSIMILAR CANDIDATE FOR NEULASTA® (PEGFILGRASTIM), HAS MET ITS PRIMARY ENDPOINTS IN THE TWO PIVOTAL CLINICAL STUDIES.  Full Article

Akorn Comments On Delaware Chancery Court Ruling
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Akorn Inc ::AKORN COMMENTS ON DELAWARE CHANCERY COURT RULING.AKORN INC - "CONTINUE TO BELIEVE FRESENIUS' ATTEMPT TO TERMINATE TRANSACTION IS IN BREACH OF OUR BINDING MERGER AGREEMENT".AKORN INC - "INTEND TO APPEAL, IN AN EFFORT TO VIGOROUSLY ENFORCE OUR RIGHTS".  Full Article

Fresenius CEO Expects Akorn Matter To Be Resolved By Early 2019
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Fresenius Se ::CEO SAYS ARE CONVINCED OF MERITS OF CASE TO TERMINATE AKORN DEAL.CEO SAYS EVEN IF COURT DOES NOT AGREE IT WAS THE RIGHT DECISION TO TERMINATE DEAL.CEO SAYS EXPECTS AKORN MATTER TO BE FINALLY RESOLVED BY EARLY NEXT YEAR.CFO SAYS LESS LIKELY TO REACH UPPER END OF 2018 SALES GUIDANCE OF 5-8 PERCENT.CEO SAYS IF WE ARE FORCED TO CLOSE AKORN DEAL, WILL NEED TO DO SOME PRETTY SUBSTANTIAL REMEDIATION REGARDLESS OF HOW FDA RESPONDS.  Full Article

Nxstage Medical Inc Says Co Agreed To Sell Its Bloodlines Business
Wednesday, 18 Jul 2018 

July 18 (Reuters) - NxStage Medical Inc ::NXSTAGE MEDICAL INC - ON JULY 10, CO AGREED TO SELL ITS BLOODLINES BUSINESS OPERATED UNDER THE MEDISYSTEMS NAME TO B. BRAUN MEDICAL INC.NXSTAGE MEDICAL INC - NXSTAGE CONTINUES TO EXPECT FRESENIUS MERGER TO CLOSE IN 2018 -SEC FILING.  Full Article

Akorn Issues Statement In Response To Fresenius Seeking To Terminate Merger
Sunday, 22 Apr 2018 

April 22 (Reuters) - Akorn Inc ::AKORN INC ISSUES STATEMENT IN RESPONSE TO FRESENIUS KABI’S ANNOUNCEMENT THAT IT IS SEEKING TO TERMINATE THE DEFINITIVE MERGER AGREEMENT.AKORN SAYS PREVIOUSLY DISCLOSED ONGOING INVESTIGATION HAS NOT FOUND ANY FACTS THAT WOULD RESULT IN ADVERSE EFFECT ON CO'S BUSINESS.AKORN SAYS SINCE INVESTIGATION DID NOT FIND ANY FACTS RESULTING IN ADVERSE EFFECT ON CO'S BUSINESS, IT IS "NO BASIS TO TERMINATE THE TRANSACTION".AKORN SAYS INTEND TO "VIGOROUSLY" ENFORCE CO'S RIGHTS, AND FRESENIUS’ OBLIGATIONS, UNDER BINDING MERGER AGREEMENT.  Full Article

Fresenius SE & Co. KGaA Fresenius Terminates Merger Agreement With Akorn
Sunday, 22 Apr 2018 

April 22 (Reuters) - Fresenius SE & Co KGaA ::DGAP-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS TERMINATES MERGER AGREEMENT WITH AKORN.  Full Article

Fresenius says US Tax Reform ‍results In One-Time Book Gain Of about 90 mln euros
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Fresenius Se ::‍NEW US TAX LEGISLATION TRIGGERS REVALUATION OF DEFERRED TAX LIABILITIES​.US TAX REFORM ‍RESULTS IN A ONE-TIME BOOK GAIN OF APPROXIMATELY EUR 90 MILLION, TO BE REFLECTED IN FRESENIUS' 2017 GROUP NET INCOME​.‍WILL REPORT FY17 RESULTS, PROVIDE FY18 GUIDANCE, INCLUDING DETAILS ON RECURRING TAX EFFECTS RESULTING FROM US TAX REFORM, ON FEB 27, 2018​.  Full Article

Deals of the day-Mergers and acquisitions

Oct 1 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: